Biotech company Pharming Group NV (NYSE Euronext: PHARM) recently announced that it will present at the 15th BIO-Europe (November 2-4, 2009) in Vienna, Austria.
Sijmen de Vries, Chief Executive Officer of Pharming, will present an update of the Company and its business at the BIO-Europe conference on Tuesday, November 3 at 11:00 am Central European Time. BIO- Europe is Europe's largest international partnering conference.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The conference attendees include delegates from Europe, North America and Asia-Pacific. For further information on the BIO-Europe 2009, please visit http://www.ebdgroup.com/bioeurope. The presentation will be available on Pharming's website after the meeting. Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with EMEA. Prodarsan® is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com. Source Pharming Group NV
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
